Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026
Same author

Waldenstrom Macroglobulinemia Leading to Cholestatic Liver Injury and Rapid Progression to Liver Failure.

ACG case reports journal·2026
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026
Same author

Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.

Leukemia & lymphoma·2026
Same author

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Blood advances·2026

Related Experiment Video

Updated: May 3, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K

Ibrutinib in B-cell Lymphomas.

Kami Maddocks1, Kristie A Blum

  • 1Department of Hematology, Arthur G James Comprehensive Cancer Center, The Ohio State University, 320 W 10th Avenue, A350C Starling Loving Hall, Columbus, OH, 43210, USA, kami.maddocks@osumc.edu.

Current Treatment Options in Oncology
|February 1, 2014
PubMed
Summary
This summary is machine-generated.

Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib offer a new oral treatment option for relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This well-tolerated therapy shows promising activity and is being explored in combination treatments.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Experiment Videos

Last Updated: May 3, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Standard frontline therapies for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) include chemoimmunotherapy and radiation.
  • Relapsed or refractory disease in these lymphomas is often incurable without stem cell transplant, which is not suitable for all patients.
  • The Bruton's tyrosine kinase (BTK) signaling pathway is crucial for the survival of these B-cell malignancies.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ibrutinib, an oral BTK inhibitor, in patients with relapsed or refractory B-cell lymphomas.
  • To highlight the potential of ibrutinib as a treatment option for patients ineligible for stem cell transplant.
  • To discuss the ongoing investigation of ibrutinib in combination therapies and other novel agents targeting the BTK pathway.

Main Methods:

  • Review of clinical data and studies on ibrutinib in B-cell lymphomas.
  • Analysis of response rates, tolerability, and toxicity profiles of ibrutinib therapy.
  • Discussion of current and future clinical trials involving ibrutinib and other BTK pathway inhibitors.

Main Results:

  • Ibrutinib has demonstrated promising activity in certain subtypes of DLBCL, relapsed/refractory FL, and relapsed/refractory MCL.
  • Ibrutinib is an orally administered, well-tolerated daily therapy with acceptable toxicity.
  • FDA approval for ibrutinib in relapsed/refractory MCL supports its consideration in first relapse settings.

Conclusions:

  • Ibrutinib represents a significant advancement in the treatment of relapsed or refractory B-cell lymphomas, offering an oral, well-tolerated alternative.
  • Its efficacy and tolerability support its use as a single agent and in combination therapies for DLBCL, FL, and MCL.
  • Further research into ibrutinib and other BTK pathway inhibitors holds promise for improving outcomes in these hematologic malignancies.